Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Hansson

Showing results (151-160 of 199) with videos related to

Pageof 20
Sort By:
The Journal of Investigative Dermatology|July 8, 2014
Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclassJohan Staaf, Katja Harbst, Martin Lauss, et al.
Cancer Immunology Research|March 29, 2018
Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate InvasivenessMalin E Winerdal, David Krantz, Ciputra A Hartana, et al.
International Journal of Cancer|November 18, 2014
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanomaRainer Tuominen, Rosalyn Jewell, Joost J van den Oord, et al.
Clinical Immunology (Orlando, Fla.)|December 28, 2016
Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancerA Ali Zirakzadeh, Johan Kinn, David Krantz, et al.
Frontiers in Immunology|January 11, 2020
Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome DisplayStina L Wickström, Tanja Lövgren, Michael Volkmar, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage IIIJean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
Journal of the National Cancer Institute|June 11, 2009
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferonMarna G Bouwhuis, Stefan Suciu, Sandra Collette, et al.
Oncoimmunology|September 14, 2020
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccinationTanja Lövgren, Maria Wolodarski, Stina Wickström, et al.
Scientific Reports|May 27, 2021
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanomaLinda Vidarsdottir, Alireza Azimi, Ishani Das, et al.
The Lancet. Oncology|May 19, 2015
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, et al.
Pageof 20

Showing results (151-160 of 199) with videos related to

Sort By:
Pageof 20
The Journal of Investigative Dermatology|July 8, 2014
Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclassJohan Staaf, Katja Harbst, Martin Lauss, et al.
Cancer Immunology Research|March 29, 2018
Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate InvasivenessMalin E Winerdal, David Krantz, Ciputra A Hartana, et al.
International Journal of Cancer|November 18, 2014
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanomaRainer Tuominen, Rosalyn Jewell, Joost J van den Oord, et al.
Clinical Immunology (Orlando, Fla.)|December 28, 2016
Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancerA Ali Zirakzadeh, Johan Kinn, David Krantz, et al.
Frontiers in Immunology|January 11, 2020
Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome DisplayStina L Wickström, Tanja Lövgren, Michael Volkmar, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage IIIJean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
Journal of the National Cancer Institute|June 11, 2009
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferonMarna G Bouwhuis, Stefan Suciu, Sandra Collette, et al.
Oncoimmunology|September 14, 2020
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccinationTanja Lövgren, Maria Wolodarski, Stina Wickström, et al.
Scientific Reports|May 27, 2021
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanomaLinda Vidarsdottir, Alireza Azimi, Ishani Das, et al.
The Lancet. Oncology|May 19, 2015
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, et al.
Pageof 20